药物回收

The United States: Update: Several companies voluntarily recall extended release metformin (English only)

The US Food and Drug Administration (FDA) is alerting patients and health care professionals to several voluntary recalls of extended release (ER) metformin by the following companies. The companies are recalling metformin due to the possibility that the medicines could contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit. The companies include:
- Avkare (repackager for Amneal) – All lots
- PD-Rx Pharmaceuticals (repackager for Amneal) – All lots
- PD-Rx Pharmaceuticals (repackager for Marksans) – All lots
- The Harvard Drug Group (repackager for Apotex) – One lot (T-02134)
- Preferred Pharmaceuticals (repackager for Marksans) – Four lots (J0119M, K1419L, K2719J, A0220H)

Please refer to the following website in FDA for details: http://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin

In Hong Kong, the above products are not registered pharmaceutical products.

Currently in Hong Kong, there are 122 registered pharmaceutical products containing metformin. All products are prescription-only medicines.

Related news on the detection of N-nitrosodimethylamine (NDMA) in metformin products was previously issued by various overseas drug regulatory authorities, and was posted on the Drug Office website since 5 Dec 2019, with the latest update posted on 9 Jul 2020. Letters to inform local healthcare professionals were issued by the Department of Health (DH) on 6 Dec 2019. The DH has contacted the certificate holders of all registered metformin products for follow up on the local impact of the issue, and collected samples of metformin-containing products in the local market for analysis. When there are any health risks identified and posed to the public, a press statement will be issued as soon as possible. The following is the main content of the press statement issued previously:
- On 11 Mar 2020, the DH endorsed a licensed wholesale dealer, the International Medical Company Ltd, to recall 3 batches of Metformin-Teva 500mg Tablets (HK-60334) (batch number: 16532717, 16532817 and 16532917) from the market due to the potential presence of NDMA in the product.

So far, the DH has received 17 cases of adverse drug reaction related to metformin. None of them is concluded to be related to the presence of NDMA. The DH will remain vigilant on the development of the issue and any safety update of the drug issued by overseas drug regulatory authorities for consideration of any action deemed necessary.

Patients who are taking metformin-containing products should not stop taking the medicines, but should seek advice from their healthcare professionals for proper arrangement.

Ends/Tuesday, Jul 14, 2020
Issued at HKT 15:00

Related Information:

The United States: Viona Pharmaceuticals Inc., issues voluntary nationwide recal... 上载于 2022-01-14

The United States: Viona Pharmaceuticals Inc. issues voluntary nationwide recall... 上载于 2021-12-29

The United Kingdom: Class 2 Medicines Recall: Rosemont Pharmaceuticals Limited, ... 上载于 2021-08-26

The United States: Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recal... 上载于 2021-06-12

The United States: Nostrum Laboratories, Inc. expands voluntary nationwide recal... 上载于 2021-01-26

The United States: Nostrum Laboratories, Inc. expands voluntary nationwide recal... 上载于 2021-01-05

Australia : Recall - Blooms the Chemist Metformin XR 1000 metformin hydrochlorid... 上载于 2020-11-18

The United States: Nostrum Laboratories, Inc. issues voluntary nationwide recall... 上载于 2020-11-04

The United States: Nostrum Laboratories, Inc. issues voluntary nationwide recall... 上载于 2020-11-03

The United States: Marksans Pharma Limited issues expansion of voluntary nationw... 上载于 2020-10-06

The United States: Sun Pharmaceutical Industries, Inc. issues voluntary nationwi... 上载于 2020-09-24